Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications.
Blood rheology alterations have often been reported in diabetic patients and may be associated with an increased risk for diabetic vascular disease. In this light a hemorheologic approach with pentoxifylline has been suggested in diabetic patients with hemorheological changes in order to improve the hemorheology approach and to evaluate the long-term effects of this treatment on the other clinical and metabolic variables. The study concerned a 10-year retrospective analysis of diabetic patients with hemorheologic alterations and angiopathic complications. Pentoxifylline (Trental 400) significantly reduced blood and plasma viscosity (at high and low shear-rates), fibrinogen and erythrocyte aggregation, and increased erythrocyte filterability throughout the study. The improvement of the hemorheologic pattern was obtained independently of the variation in glycometabolic control and body weight changes, whereas concomitant reductions of arterial blood pressure levels and of urinary excretion of albumin and total proteins was observed during the treatment. Pentoxifylline might therefore be successfully employed for long-term periods in the treatment of hemorheologic disorders in diabetic patients without effects on the metabolic pattern.
Solerte
S B
SB
Department of Internal Medicine and Medical Therapy, School of Medicine, University of Pavia, Italia.
Fioravanti
M
M
Cerutti
N
N
Severgnini
S
S
Locatelli
M
M
Pezza
N
N
Rondanelli
M
M
Trecate
L
L
Balza
G
G
Ferrari
E
E
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D003925:Diabetic Angiopathies / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D010431:Pentoxifylline / Q000627:therapeutic use*; D012189:Retrospective Studies; D012212:Rheology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D005340:Fibrinogen; D010431:Pentoxifylline